Short Interest in Caring Brands, Inc. (NASDAQ:CABR) Declines By 71.0%

Caring Brands, Inc. (NASDAQ:CABR) was the recipient of a large decrease in short interest during the month of May. As of May 15th, there was short interest totaling 5,492 shares, a decrease of 71.0% from the April 30th total of 18,964 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily volume of 100,261 shares, the days-to-cover ratio is presently 0.1 days.

Institutional Investors Weigh In On Caring Brands

A hedge fund recently bought a new stake in Caring Brands stock. Jane Street Group LLC bought a new position in shares of Caring Brands, Inc. (NASDAQ:CABR) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.25% of Caring Brands at the end of the most recent quarter.

Caring Brands Price Performance

CABR traded down $0.05 on Friday, reaching $1.11. 66,922 shares of the company’s stock were exchanged, compared to its average volume of 97,999. The firm has a market capitalization of $10.09 million and a PE ratio of -1.73. The company has a current ratio of 5.66, a quick ratio of 5.62 and a debt-to-equity ratio of 0.03. Caring Brands has a twelve month low of $0.71 and a twelve month high of $5.35. The business has a fifty day moving average price of $1.08.

Caring Brands (NASDAQ:CABR) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.27) earnings per share (EPS) for the quarter.

Caring Brands Company Profile

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.